Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Jpn J Clin Oncol. 2010 Jun;40(6):596-9. doi: 10.1093/jjco/hyq025. Epub 2010 Mar 3.
There is no established chemotherapy for anaplastic thyroid cancer. We conducted a prospective feasibility study at a single center to explore the antitumor activity of docetaxel against anaplastic thyroid cancer. Docetaxel was administered intravenously at a dose of 60 mg/m(2) over the course of 1 h every 3 weeks in patients with anaplastic thyroid cancer who had received no prior chemotherapy. A total of seven patients with anaplastic thyroid cancer were enrolled over the course of 30 months and received docetaxel. The treatment response was complete response in one patient, stable disease in two and progressive disease in four. The response rate was 14%, and the disease control rate (complete response plus stable disease) was 43%. The median time to progression was 6 weeks (range, 1-50). Toxicity was tolerable. Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity.
未分化甲状腺癌尚无标准的化疗方案。我们在单中心开展了一项前瞻性可行性研究，以探索多西紫杉醇治疗未分化甲状腺癌的抗肿瘤活性。对既往未接受过化疗的未分化甲状腺癌患者，采用多西紫杉醇 60mg/m2 剂量，1 小时静脉滴注，每 3 周 1 次。在 30 个月的时间里，共纳入 7 例未分化甲状腺癌患者接受多西紫杉醇治疗。1 例患者获得完全缓解，2 例患者疾病稳定，4 例患者疾病进展。客观缓解率为 14%，疾病控制率（完全缓解+疾病稳定）为 43%。中位无进展生存期为 6 周（范围：1-50 周）。毒性可耐受。多西紫杉醇可能是一种治疗未分化甲状腺癌的有效药物，具有可耐受的毒性。
